Table 1.
Patient characteristics and TST results
| Total N=4,114 | CD4≤350 N=2,138 | CD4>350 N=1,976 | p-value | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Female sex | 1,553 (38%) | 758 (35%) | 795 (40%) | 0.002 |
| Median age, years (IQR) | 35 (28–43) | 37 (30–45) | 33 (27–41) | <0.001 |
| Prior ART | 382 (9%) | 180 (8%) | 202 (10%) | 0.05 |
| Median days on ART (IQR) | 690 (162–1,689) | 332 (78–1,237) | 973 (281–2,017) | <0.001 |
| TST results | ||||
| TST-negative | 2,265 (55%) | 1,202 (56%) | 1,063 (54%) | <0.001 |
| TST-positive* | 657 (16%) | 278 (13%) | 379 (19%) | |
| TST-unknown** | 1,192 (29%) | 658 (31%) | 534 (27%) | |
| Median days to TST (IQR) | 46 (10–180) | 45 (11–210) | 47 (9–165) | 0.17 |
| ART at TST | 1,181 (40%) | 772 (52%) | 409 (28%) | <0.001 |
Abbreviations: IQR, interquartile range; ART, antiretroviral therapy; TST, tuberculin skin test
*
Includes 155 patients who converted from TST-negative to -positive over follow-up
**
TST not placed and/or read